Identifying Resistance Mechanisms against Five Tyrosine Kinase Inhibitors Targeting the ERBB/RAS Pathway in 45 Cancer Cell Lines

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Pénzváltó, Zsófia ^a   Tegze, Bálint ^a   Szász, A Marcell ^a   Sztupinszki, Zsófia ^a   Likó, István ^b   Szendroi, Attila ^c   Schäfer, Reinhold ^d   Gyorffy, Balázs ^d,e  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b GEDEON RICHTER LTD   (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTACTIC FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITHELIAL CELL ADHESION MOLECULE; ERLOTINIB; GEFITINIB; GLYCEROPHOSPHOINOSITOL INOSITOLPHOSPHODIESTERASE; LAPATINIB; PROTEIN LGALS8; PROTEIN RAB17; RAB PROTEIN; RAS PROTEIN; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG;

ADULT; ANXA3 GENE; ARTICLE; CANCER CELL CULTURE; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG TARGETING; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY METASTASIS; MALE; MICROARRAY ANALYSIS; OVERALL SURVIVAL; RAB25 GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CARCINOMA, RENAL CELL; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRROLES; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSCRIPTOME;

EID: 84875540660     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059503     Document Type: Article

References (52)

1. Gyorffy B, Schafer R, (2010) Biomarkers downstream of RAS: a search for robust transcriptional targets. Curr Cancer Drug Targets 10: 858-868.
2. Cohen AJ, Mankey J, Wendt W, (2003) Response: the claims of public health and public safety. Sci Pract Perspect 2: 15-17.
3. Gomez HL, Doval DC, Chavez MA, Ang PC, Aziz Z, et al. (2008) Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 26: 2999-3005.
4. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134.
5. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124.
6. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R, (2003) FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 8: 303-306.
7. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, et al. (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112: 533-543.
8. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733-2743.
9. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, et al. (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 3584-3590.
10. Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, et al. (2008) Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 26: 127-131.
11. Zhou W, Ercan D, Chen L, Yun CH, Li D, et al. (2009) Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462: 1070-1074.
12. Armato SG, 3rd, McNitt-Gray MF, Reeves AP, Meyer CR, McLennan G, et al (2007) The Lung Image Database Consortium (LIDC): an evaluation of radiologist variability in the identification of lung nodules on CT scans. Acad Radiol 14: 1409-1421.
13. Huang D, Ding Y, Zhou M, Rini BI, Petillo D, et al. (2010) Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 70: 1063-1071.
14. Marks JL, Broderick S, Zhou Q, Chitale D, Li AR, et al. (2008) Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol 3: 111-116.
15. Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, et al. (2011) Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol 29: 166-173.
16. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, et al. (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26: 5705-5712.
17. Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, et al. (2009) PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69: 1851-1857.
18. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, et al. (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2: e17.
19. Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Janne PA, et al. (2009) Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 15: 5267-5273.
20. Lugthart S, Cheok MH, den Boer ML, Yang W, Holleman A, et al. (2005) Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell 7: 375-386.
21. Gyorffy B, Serra V, Jurchott K, Abdul-Ghani R, Garber M, et al. (2005) Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival. Oncogene 24: 7542-7551.
22. Huang F, Reeves K, Han X, Fairchild C, Platero S, et al. (2007) Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 67: 2226-2238.
23. Coldren CD, Helfrich BA, Witta SE, Sugita M, Lapadat R, et al. (2006) Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol Cancer Res 4: 521-528.
24. Balko JM, Potti A, Saunders C, Stromberg A, Haura EB, et al. (2006) Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors. BMC Genomics 7: 289.
25. Akcakanat A, Zhang L, Tsavachidis S, Meric-Bernstam F, (2009) The rapamycin-regulated gene expression signature determines prognosis for breast cancer. Mol Cancer 8: 75.
26. Gyorffy B, Surowiak P, Kiesslich O, Denkert C, Schafer R, et al. (2006) Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer 118: 1699-1712.
27. Gautier L, Cope L, Bolstad BM, Irizarry RA, (2004) affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20: 307-315.
28. Gyorffy B, Molnar B, Lage H, Szallasi Z, Eklund AC, (2009) Evaluation of microarray preprocessing algorithms based on concordance with RT-PCR in clinical samples. PLoS One 4: e5645.
29. Tusher VG, Tibshirani R, Chu G, (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98: 5116-5121.
30. Breitling R, Herzyk P, (2005) Rank-based methods as a non-parametric alternative of the T-statistic for the analysis of biological microarray data. J Bioinform Comput Biol 3: 1171-1189.
31. Breitling R, Armengaud P, Amtmann A, Herzyk P, (2004) Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett 573: 83-92.
32. Jeffery IB, Higgins DG, Culhane AC, (2006) Comparison and evaluation of methods for generating differentially expressed gene lists from microarray data. BMC Bioinformatics 7: 359.
33. Tibshirani R, Hastie T, Narasimhan B, Chu G, (2002) Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 99: 6567-6572.
34. Dietmann S, Lee W, Wong P, Rodchenkov I, Antonov AV, (2010) CCancer: a bird's eye view on gene lists reported in cancer-related studies. Nucleic Acids Res 38: W118-123.
35. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634.
36. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, et al. (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483: 603-607.
37. Minematsu T, Giacomini KM, (2011) Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther 10: 531-539.
38. Widemann BC, Kim A, Fox E, Baruchel S, Adamson PC, et al. (2012) A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res 18: 6011-6022.
39. Delgado VM, Nugnes LG, Colombo LL, Troncoso MF, Fernandez MM, et al. (2011) Modulation of endothelial cell migration and angiogenesis: a novel function for the "tandem-repeat" lectin galectin-8. FASEB J 25: 242-254.
40. Cludts S, Decaestecker C, Mahillon V, Chevalier D, Kaltner H, et al. (2009) Galectin-8 up-regulation during hypopharyngeal and laryngeal tumor progression and comparison with galectin-1,-3 and-7. Anticancer Res 29: 4933-4940.
41. Lutcke A, Jansson S, Parton RG, Chavrier P, Valencia A, et al. (1993) Rab17, a novel small GTPase, is specific for epithelial cells and is induced during cell polarization. J Cell Biol 121: 553-564.
42. Munz M, Baeuerle PA, Gires O, (2009) The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 69: 5627-5629.
43. Varga M, Obrist P, Schneeberger S, Muhlmann G, Felgel-Farnholz C, et al. (2004) Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res 10: 3131-3136.
44. Miyake M, Nakano K, Itoi SI, Koh T, Taki T, (1996) Motility-related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer. Cancer Res 56: 1244-1249.
45. Weinstein IB, Joe AK, (2006) Mechanisms of disease: Oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3: 448-457.
46. Suda K, Tomizawa K, Osada H, Maehara Y, Yatabe Y, et al. (2012) Conversion from the "oncogene addiction" to "drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation. Lung Cancer 76: 292-299.
47. Jung EJ, Moon HG, Park ST, Cho BI, Lee SM, et al. (2010) Decreased annexin A3 expression correlates with tumor progression in papillary thyroid cancer. Proteomics Clin Appl 4: 528-537.
48. Yan X, Yin J, Yao H, Mao N, Yang Y, et al. (2010) Increased expression of annexin A3 is a mechanism of platinum resistance in ovarian cancer. Cancer Res 70: 1616-1624.
49. Ruan L, Wang GL, Chen Y, Yi H, Tang CE, et al. (2010) Identification of tyrosine phosphoproteins in signaling pathway triggered TGF-a by using functional proteomics technology. Med Oncol 27: 1407-1414.
50. Peraldo-Neia C, Migliardi G, Mello-Grand M, Montemurro F, Segir R, et al. (2011) Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer. BMC Cancer 11: 31.
51. Nam KT, Lee HJ, Smith JJ, Lapierre LA, Kamath VP, et al. (2010) Loss of Rab25 promotes the development of intestinal neoplasia in mice and is associated with human colorectal adenocarcinomas. J Clin Invest 120: 840-849.
52. Cheng JM, Volk L, Janaki DK, Vyakaranam S, Ran S, et al. (2010) Tumor suppressor function of Rab25 in triple-negative breast cancer. International Journal of Cancer 126: 2799-2812.